Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | IGF1R | P08069 | 2/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13649082 | 0.83 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1KMT2AMEN1IGF1R | |
| SCHEMBL1936518 | 0.83 | ALDH1A1 (0.71) | ALDH1A1L3MBTL1KMT2AMEN1KDM4E | |
| SCHEMBL9278122 | 0.81 | ALDH1A1 (0.69) | ALDH1A1L3MBTL1KMT2AMEN1KDM4E | |
| SCHEMBL27635201 | 0.78 | STK17B (0.44) | ALDH1A1L3MBTL1KMT2AMEN1IGF1R | |
| SCHEMBL13897499 | 0.77 | MEN1 (0.52) | ALDH1A1L3MBTL1KMT2AMEN1IGF1R | |
| SCHEMBL13194676 | 0.77 | KMT2A (0.46) | ALDH1A1L3MBTL1KMT2AMEN1IGF1R | |
| SCHEMBL6210647 | 0.75 | MEN1 (0.42) | ALDH1A1L3MBTL1KMT2AMEN1IGF1R | |
| SCHEMBL6210640 | 0.75 | MEN1 (0.42) | ALDH1A1L3MBTL1KMT2AMEN1IGF1R | |
| SCHEMBL5151737 | 0.75 | STK17A (0.50) | ALDH1A1L3MBTL1KMT2AMEN1STK17B | |
| SCHEMBL3447092 | 0.75 | KMT2A (0.50) | ALDH1A1L3MBTL1KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-7973044-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7968547-B2 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100160343-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-7741328-B2 | Treating inflammatory diseases such as rheumatoid arthritis, multiple sclerosis or Crohn's disease; Very Late Antigen-4 (VLA-4), also called alpha 4 beta 1 integrin; N-(sulfonamido-substituted pyrimidyl, pyridyl or pyrazyl)-L-4-(N,N-dimethylcarbamyloxy)phenylalanine compounds | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20040266763-A1 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6794506-B2 | TREATMENT OF INFLAMMATORY DISEASES, SUCH AS ASTHMA, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, AIDS DEMENTIA, DIABETES, INFLAMMATORY BOWEL DISEASE, RHEUMATOID ARTHRITIS, TISSUE TRANSPLANTATION, TUMOR METASTASIS | ELAN PHARMACEUTICALS, INC. | 2004-09-21 | — | — | US | disclosed |
| US-20040147512-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20030139402-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated byVLA-4 | KONRADI ANDREI W (US) | 2003-07-24 | — | — | US | disclosed |
| US-20030125324-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2003-07-03 | — | — | US | disclosed |
| US-6492372-B1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020052375-A1 | 3-(Heteroaryal) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2002-05-02 | — | — | US | disclosed |
| WO-2002008203-A2 | 3-(HETEROARYL) ALANINE DERIVATIVES-INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-1144388-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | Elan Pharmaceuticals, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043372-A1 | ACYL DERIVATIVES WHICH TREAT VLA-4 RELATED DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139402-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated byVLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 386/4885L3MBTL1 164/4885KMT2A 686/4885 |
| US-20040266763-A1 | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, AADAT, ICAM1 | ALDH1A1 376/4885L3MBTL1 113/4885KMT2A 901/4885 |
| US-20100160341-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 260/4885L3MBTL1 427/4885KMT2A 685/4885 |
| US-20030125324-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 260/4885L3MBTL1 427/4885KMT2A 685/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | ALDH1A1 1780/4885L3MBTL1 2247/4885KMT2A 2222/4885 |
| US-20040147512-A1 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 260/4885L3MBTL1 427/4885KMT2A 685/4885 |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | ALDH1A1 3377/4885L3MBTL1 3251/4885KMT2A 1642/4885 |
| US-20020052375-A1 | 3-(Heteroaryal) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGAL | ALDH1A1 572/4885L3MBTL1 127/4885KMT2A 1839/4885 |
| US-20100160343-A1 | HETEROARYL, HETEROCYCLIC AND ARYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | VCAM1, ICAM1, ITGB4 | ALDH1A1 260/4885L3MBTL1 427/4885KMT2A 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.